What Is the Medicare GLP-1 Bridge Program?
Medicare is finally opening the door to affordable weight loss drugs. Starting July 1, 2026, eligible Medicare beneficiaries can access GLP-1 medications for just $50 a month through a new pilot initiative. The Centers for Medicare & Medicaid Services (CMS) announced the Medicare GLP-1 Bridge, a short-term program designed to close the affordability gap before a longer-term solution potentially launches in 2028.
This marks a historic shift. Traditionally, Medicare has been barred from covering obesity treatments. Now, for the first time, the program extends GLP-1 drug coverage to millions of seniors and disabled Americans who previously had no affordable path to these medications.
The Bridge program runs from July 1, 2026, through December 31, 2027. It covers three specific GLP-1 medications approved for weight loss:
- Wegovy (both pill and injectable forms)
- Zepbound (KwikPen formulation only)
- Foundayo (pill form)
Without insurance, these drugs can cost anywhere from $149 to $699 per month. The flat $50 copay is, therefore, a significant financial relief for many patients.
Who Qualifies for the Bridge Program?
BMI and Health Requirements
Not every Medicare beneficiary automatically qualifies. CMS has set clear eligibility criteria based on body mass index (BMI) and underlying health conditions. Specifically, you qualify if you meet either of these conditions:
- BMI of 27 or higher plus a related health condition such as heart disease, prediabetes, or hypertension
- BMI of 35 or higher, which grants automatic eligibility regardless of other health conditions
According to the CDC, approximately 40% of American adults are clinically obese, with a BMI of 30 or above. Consequently, tens of millions of people could potentially meet these thresholds.
Insurance Enrollment Requirements
Additionally, you must be enrolled in a Medicare Part D plan, which covers prescription drugs. However, the Bridge program itself operates outside the standard Part D process, which makes it somewhat unique.
If you are already taking a GLP-1 drug for weight loss, you may still qualify. Your prescribing doctor simply needs to confirm that you met the BMI criteria when you first started the medication — even if your BMI has since dropped.
How Does the Program Work?
The process differs from a standard Part D prescription. Instead of routing through your regular plan, your doctor submits a prior authorization request to a central system managed by Humana, a CMS contractor. Importantly, doctors do not need to be enrolled as Medicare providers to prescribe under this program or file a prior authorization.
Once CMS approves the request, patients pay the flat $50 copay directly at the pharmacy. Furthermore, the copay stays fixed at $50 regardless of dosage — an unusual feature that benefits patients who need higher doses to maintain weight loss.
Key Benefits of the GLP-1 Bridge
The most obvious benefit is cost savings. Consider the comparison: cash prices for Wegovy injectables range from $199 to $399 per month. Zepbound’s KwikPen can reach $699 monthly. Foundayo tops out at $349 per month. Against those figures, a predictable $50 copay is transformative.
Moreover, the program lowers barriers for patients who need long-term therapy. Most research confirms that GLP-1 users require continued use and higher doses to sustain weight loss. The Bridge program’s flat-rate copay protects patients from escalating costs as their dosage increases.
Important Limitations to Know
Copay Does Not Count Toward Out-of-Pocket Cap
Despite the savings, the Bridge program comes with notable restrictions. The $50 copay does not count toward the Part D annual deductible. It also does not apply toward the $2,100 annual out-of-pocket cap on prescription drug spending. This means patients bear the copay cost entirely outside the usual Medicare cost-protection structure.
Low-Income Beneficiaries Face Challenges
Furthermore, beneficiaries who receive the Extra Help low-income subsidy cannot apply that assistance toward Bridge program drugs. For seniors accustomed to paying $5 or $10 copays, the $50 monthly charge can still present a serious financial hurdle.
As Juliette Cubanski of KFF noted, fifty dollars sounds reasonable compared to retail prices. Yet, for someone living on a $750 monthly Social Security check, it remains a significant burden.
Additionally, GLP-1 drugs approved for conditions other than obesity — such as Type 2 diabetes or cardiovascular risk reduction — remain under standard Part D. This creates an unusual situation where the same drug may cost different amounts depending on the medical reason it is prescribed.
What Happens After December 2027?
The Bridge program’s long-term future remains uncertain. CMS originally planned a six-month pilot, after which insurers would absorb more of the drug costs under a voluntary long-term program. However, too few insurers signed on by the April 2026 deadline. As a result, CMS extended the Bridge program to 18 months.
The extension buys time for insurers to collect usage data and negotiate terms with the Trump administration. Nevertheless, it also places a heavy financial burden on Medicare itself.
Analysts at KFF estimate the extended program could cost Medicare billions of dollars per year. Notably, CMS has not released any public cost projections. A separate KFF analysis found that nearly 14 million Medicare beneficiaries were overweight or obese as of 2020 — suggesting enormous potential demand.
The ultimate shape of post-2027 coverage remains unclear. For now, the Bridge program offers a critical lifeline to millions of Americans seeking affordable access to proven weight loss therapies.
